nGageIT Digital Health is pleased to announce the roll-out of our groundbreaking Mobile Breath NanoSensor prototype to detect Lung Cancer and COPD from the exhaled breath in September 2019. nGageIT Digital Health, a company based in Toronto, Ontario and Cleveland, Ohio, has deep knowledge of tailored breath nanosensor fabrication technology as well as services for healthcare organizations that help them identify critical patient challenges and implement high-value novel breath-based disease monitoring and screening tools. nGageIT’s intelligent nanosensors make your exhaled breath their value proposition.
Using single breath samples, the Airostotle™ nanosensor is designed to detect early-stage cancer and recurrence of disease through simultaneous detection of unique AI enhanced breath VOC signatures with high clinical sensitivity and specificity.
Airostotle™ exhaled breath sensor for Cancer will be used by top-tier academic research networks and bio-pharmas in studies involving adjuvant therapy decision-making, recurrence monitoring, and screening for early-stage cancer.
nGageIT Digital Health is focusing initially on three key tumor types: lung, colorectal, and breast cancers with preliminary data on lung cancer detection available September 2019.
Please feel free to reach out to us in person at Bio2019 to discuss the opportunity for your company, or send us an email here.